The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy. The FDA is reviewing a nasal spray ...

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.

Individuals with social risk factors at the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have increased risk for subsequent long COVID.

There is lower incidence of nonlacunar covert infarcts among patients with cryptogenic stroke and atrial cardiopathy treated with apixaban.

Maternal hypertension is independently associated with risk for adverse neurodevelopment outcomes in preterm infants, according to research results published in JAMA Network Open. Multiple studies ...

The FDA has approved a labeling update for Leqvio (inclisiran) allowing for first-line use in the treatment of hypercholesterolemia.

Copper oxide impregnated dressings were cheaper, more convenient, and faster to apply when compared with negative pressure wound therapy for the treatment of diabetic foot wounds.

The FDA has granted clearance for the CardioTag device to assess cardiac function and improve patient outcomes across various healthcare settings.

GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Three of the most widely studied healthy dietary patterns are associated with lower incidence of type 2 diabetes (T2D), regardless of an individual's ethnicity.

Gallstone disease is linked to metabolic disorders, such as obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease.

Dr Samantha Philip and Dr Kathryn E Kyler discuss the impact of weight bias in healthcare and ways for physicians to be more weight inclusive.